SAE Media Group’s Inaugural Respiratory Drug Delivery will be coming to London in November 2023 to bring together big pharma, device developers and innovative biotech to discuss emerging trends and innovations within respiratory drug delivery device development. The conference will bring the opportunity for experts to discuss emerging trends and innovations in the inhalator drug delivery space.

With an increasing need for respiratory medicines and pulmonary delivery providing an alternative to common routes of delivery such as injection and oral administration, there have been significant advances in nasal and inhalation devices in recent years.

The conference is set to explore the design and development of respiratory drug delivery devices, opportunities for enhancing the patient experience and the digital integration of inhaler devices. Furthermore, with the growing need for circular economy, the conference will assess case studies of sustainable approaches for device life cycle management and packaging. The conference will also address challenges in regulations with case studies on labelling and best practices for successful submissions.

This event will bring you the key insights needed to expand you device portfolio and the opportunity to network with senior players throughout the industry. We hope to welcome you to this must attend event in November 2023.

Benefits of attending: Discover the latest approaches to enable sustainability for respiratory devices with a case study on an inhaler platform with a near-zero carbon footprint propellant
Benchmark against connected inhaler case studies and gain insight into how digital integration can enable better patient experience and adherence
Explore key drug formulation and biopharmaceutical considerations for efficient delivery to the respiratory system with key insights from AstraZeneca on biopharmaceutic modelling
Delve into the latest strategies to enhance patient usability for increased correct device use and better health outcomes
Hear from the MHRA, BSI and GSK on the latest regulatory requirements for respiratory devices, including Article 117, and ensuring legacy devices are in line with updated regulations